Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
Rotavac probably leads to lower severe cases of rotavirus diarrhoea compared with placebo (moderate certainty).
Rotavac probably leads to lower severe cases of all‐cause diarrhoea compared with placebo (moderate certainty).
It is very uncertain whether rotavac changes all‐cause death compared with placebo (very low certainty).
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
It is very uncertain whether fluoxetine changes response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).
Dopamine agonist showed no clear difference in live birth rate compared with placebo/no intervention (low certainty).
Dopamine agonist showed no clear difference in clinical pregnancy rate compared with placebo/no intervention (low certainty).
It is very uncertain whether dopamine agonist changes multiple pregnancy rate compared with placebo/no intervention (very low certainty).
Dopamine agonist showed no clear difference in miscarriage rate compared with placebo/no intervention (low certainty).
It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).
Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).
Coenzyme Q10 showed no clear difference in myocardial infarction compared with placebo or conventional therapy (low certainty).